Femasys (NASDAQ:FEMY) Issues Quarterly Earnings Results

Femasys (NASDAQ:FEMY) issued its quarterly earnings results on Friday. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.07, Zacks reports. Femasys had a negative net margin of 534.36% and a negative return on equity of 225.97%.

Femasys Price Performance

Shares of Femasys stock traded up $0.02 on Friday, hitting $1.42. 52,887 shares of the company traded hands, compared to its average volume of 251,829. The stock has a market capitalization of $11.90 million, a P/E ratio of -0.40 and a beta of -2.13. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.55 and a current ratio of 2.14. Femasys has a 52 week low of $1.25 and a 52 week high of $20.80. The business has a 50-day simple moving average of $1.99 and a 200 day simple moving average of $5.67.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on FEMY. Lake Street Capital reduced their price objective on shares of Femasys to $10.00 and set a “buy” rating for the company in a research note on Tuesday, August 18th. Maxim Group lowered their target price on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Wall Street Zen downgraded shares of Femasys from a “sell” rating to a “strong sell” rating in a report on Sunday, November 8th. Finally, Weiss Ratings lowered Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

About Femasys

Femasys Inc. is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures. Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.